Microbial therapeutics: New opportunities for drug delivery.

Miguel JimenezRobert LangerGiovanni Traverso

Published in: The Journal of experimental medicine (2019)

With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of administering live microorganisms to patients and the opportunities for drug delivery of these new complex therapeutics.

Keyphrases

drug delivery
clinical trial
end stage renal disease
microbial community
ejection fraction
chronic kidney disease
small molecule
newly diagnosed
cancer therapy
prognostic factors
peritoneal dialysis
drug release
patient reported outcomes